Buy Fenistil Pencivir cream 2 g
  • Buy Fenistil Pencivir cream 2 g

Penciclovir

Novartis
Dosage form
Brand & Manufacturer
Package Size
$30.81
Quantity
There are not enough products in stock
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Fenistil pencivir has an antiviral effect.

Indications

Recurrent herpes simplex with localization on the lips (herpes labialis).

Composition

1 g of cream contains penciclovir 10 mg; excipients: cetomacrogol 1000, cetostearyl alcohol, soft white paraffin, vaseline oil (liquid paraffin), propylene glycol, purified water.

No customer reviews for the moment.

Write your review

Write your review

Penciclovir

Dosage and Administration

Cuprenil take orally, 1-2 hours before meals or 2 hours after a meal or other drugs. To wash down exclusively with water.

When Wilson's disease - Konovalov: for adults - at the beginning of treatment 250 mg / day, gradually increasing the dose to 1500 mg, rarely up to 2000 mg / day. The daily dose is taken fractionally during the day. The dose of Cuprenil is considered effective if the daily excretion of copper in the urine (after 1 week of treatment) exceeds 2 mg. In the future, the adequacy of the dose is determined on the basis of the level of free copper in the serum (not less than 10 μg / ml). Children - 20 mg / kg / day, the maximum daily dose - 500 mg.

In acute metal poisoning: adults - 750-1500 mg / day, children - 30-40 mg / kg / day.

With cystinuria: adults - 750-2000 mg / day with simultaneous prescription of vitamin B6 and compensation for copper deficiency, for children - 90 mg / kg / day.

In rheumatoid arthritis and scleroderma: Initial dose of Cuprenyl is 125 mg / day for the first week with regular general blood and urine tests. From the second week, the dose is increased to 250 mg / day, from the third to 375 mg / day. Treatment with the last dose (375 mg / day) is carried out every day for 3 months. The maximum dose of Cuprenil is 500 mg / day; if it is ineffective, treatment is canceled. With the improvement of the condition, the treatment is continued for 1-2 years, gradually reducing the dose to 250 mg, taken 1 time in 2 days.

With alcoholic cirrhosis of the liver: on an empty stomach, no less than 1 hour before or 2 hours after a meal (recommended before dinner), and no earlier than 1 hour after taking any other drugs, 250-125 mg once a day. Therapy is carried out under careful control of the activity of ALT and AST in the blood plasma.

Adverse reactions

  • On the part of the digestive system: anorexia, nausea, vomiting, diarrhea, aphthous stomatitis, glossitis, intrahepatic cholestasis, pancreatitis.
  • On the part of the hematopoietic system: eosinophilia, thrombocytopenia, leukopenia, anemia (aplastic or hemolytic), agranulocytosis.
  • On the part of the respiratory system: interstitial pneumonitis, diffuse fibrosing alveolitis, Goodpasture syndrome.
  • From the side of the central nervous system and peripheral nervous system: complete loss or distortion of taste sensations; rarely reversible polyneuritis (associated with vitamin B6 deficiency).
  • Dermatological reactions: skin rash, epidermal necrolysis, alopecia.
  • Allergic reactions: allergic alveolitis, fever, polymyositis, dermatomyositis, lupus-like reactions (arthralgia, myalgia, erythematous rash, appearance of antinuclear antibodies and antibodies to DNA).
  • Other: nephritis, an increase in the mammary glands with the development of galactorrhea (in women), myasthenia.

Contraindications

  • hypersensitivity;
  • agranulocytosis;
  • systemic lupus erythematosus;
  • myasthenia gravis;
  • renal failure.

Drug interactions

Iron preparations reduce the absorption of penicillamine and weaken its therapeutic effect.

Penicillamine enhances the neurotoxic effect of isoniazid.

With simultaneous use with penicillamine, a decrease in the level of digoxin in the blood plasma is possible.

Pregnancy and Lactation

During pregnancy in patients with Konovalov-Wilson's disease or cystinuria, penicillamine therapy is continued at a dose of no more than 1 g / day, in patients with rheumatoid arthritis, penicillamine is canceled.

If necessary, the use of penicillamine during lactation should stop breastfeeding.

Special instructions

Given the possibility of serious, sometimes life-threatening adverse reactions (especially frequent in patients with rheumatoid arthritis), penicillamine is used only under constant medical supervision. During treatment, a urinalysis and a clinical blood test should be monitored 1 time in 2 weeks during the first 6 months of treatment, and then monthly; 1 time in 6 months control liver function.

In case of Konovalov-Wilson's disease or cystinuria, along with penicillamine, vitamin B is prescribed to be taken continuously.6 (due to dietary restrictions used to treat these diseases); With prolonged treatment, these patients should be regularly X-ray or ultrasound of the kidneys and urinary tract. If signs of vitamin B deficiency develop6 In patients with rheumatoid arthritis, as well as if the symptoms of this deficiency do not go away on their own, vitamin B is also prescribed.6 at a dose of 25 mg / day.

A slow, gradual increase in the dose of penicillamine reduces the incidence of some adverse reactions. If a fever, lung, liver, severe hematological or neurological disorders, myasthenia, hematuria, lupus-like reactions, or other serious adverse reactions develop during the treatment, penicillamine is canceled and, if necessary, GCS is administered. In the case of the development of isolated proteinuria, if it does not increase and does not exceed 1 g / day, treatment with penicillamine is continued, in other cases it is canceled.

  • Brand name: Fenistil Pencivir
  • Active ingredient: Penciclovir
  • Dosage form: Cream.
  • Manufacturer: Novartis
  • Country of Origin: Switzerland

Studies and clinical trials of Penciclovir (Click to expand)

  1. Synthesis of carbon-14 labelled 2-amino-9-(3-hydroxymethyl-4-isopropoxycarbonyloxybut-1-yl)purine (SK1875), a potential prodrug of penciclovir
  2. Determination of penciclovir in human plasma by liquid chromatography–electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study
  3. ChemInform Abstract: Synthesis and Evaluation of 2-Amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as Potential Prodrugs of Penciclovir.
  4. Selective and Practical Synthesis of Penciclovir.
  5. New Convenient Synthesis of Fluorinated Penciclovir Analogues 9-(4-Fluoro-3-hydroxymethylbutyl) Guanine (FHBG) (VII) and 2-Amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbutyl) Purine (6-Fluoropenciclovir) (XII).
  6. Use of isotopically chiral [4′-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract
  7. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1- and HSV-2-infected cells and by HSV-1-encoded thymidine kinase
  8. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
  9. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
  10. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient
  11. Comparison of high-performance liquid chromatography and capillary zone electrophoresis in penciclovir biodegradation kinetic studies
  12. Formulation design of microemulsion for dermal delivery of penciclovir
  13. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery
  14. Microemulsion-based hydrogel formulation of penciclovir for topical delivery
  15. Synthesis and evaluation of amino acid ester prodrugs of penciclovir
  16. A population pharmacokinetic model for penciclovir in human eye and plasma
  17. Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor
  18. Development and validation of a high-performance liquid chromatography–tandem mass spectrometry for the determination of penciclovir in human plasma: Application to a bioequivalence study
  19. Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection
  20. The new convenient synthesis of fluorinated Penciclovir analogues 9-(4-fluoro-3-hydroxymethylbutyl) guanine (FHBG) and 2-amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbutyl) purine (6-Fluoropenciclovir)
  21. Penciclovir solubility in Eudragit films: a comparison of X-ray, thermal, microscopic and release rate techniques
  22. Practical syntheses of penciclovir and famciclovir from N2-acetyl-7-benzylguanine
  23. Synthesis and stereochemical characterisation of platinum(II) complexes with the antiviral agents penciclovir and famciclovir
  24. Convenient syntheses of 9-[4-hydroxy-3-(hydroxymethyl)butyl]guanine (penciclovir) and 9-[4-acetoxy-3-(acetoxymethyl)butyl]-2-amino-9H-purine (famciclovir)

8 other products in the same category:

arrow_upward